DEA Issues Temporary Order Scheduling Synthetic Kratom Compounds as Schedule I

The Drug Enforcement Administration on Wednesday issued a temporary order placing three synthetic kratom-derived compounds in Schedule I of the Controlled Substances Act, citing an "imminent hazard to public safety" after the substances were linked to dozens of fatal overdoses nationwide.

The order, published in the Federal Register, targets mitragynine pseudoindoxyl, MGM-15, and MGM-16 — potent opioid compounds that do not occur naturally in the kratom plant but have been marketed to consumers under the guise of botanical supplements. The temporary scheduling, which takes effect immediately and will last for up to two years, represents the culmination of a federal regulatory process that began with notices of intent earlier this summer.

Scope of the overdose crisis

From February 2025 to May 2026, mitragynine pseudoindoxyl was linked to at least 56 overdose cases, of which 48 were fatal, according to DEA data. In a shorter timeframe from February to April 2026, MGM-15 was tied to 17 overdose cases, 16 of them fatal. The compounds have emerged as particularly dangerous adulterants in an evolving illicit drug market where manufacturers exploit regulatory gaps to sell potent opioids through legitimate retail channels.

"The DEA bases this action on a finding that placing these substances in Schedule I is necessary to avoid an imminent hazard to public safety," the agency stated in its Federal Register filing. The classification places the compounds in the same regulatory category as heroin and LSD, carrying the strictest criminal penalties for manufacture, distribution, and possession.

How the products reached consumers

The targeted substances have been sold under brand names including Kama, Hydroxie, Fruity Perks, and Happie Tabs, available through online vendors, gas stations, corner stores, and vape shops. Unlike raw kratom leaf, which has been used traditionally in Southeast Asia, these products represent concentrated alkaloid formulations deliberately manufactured for recreational use.

Federal investigators found that manufacturers employed sophisticated marketing strategies designed to obscure the true nature of the substances. Products were frequently labeled as "botanical extracts," "precision-formulated," or "mood boosters," with flavors such as pink lemonade, candy apple, and mango. A DEA analysis of 51 products containing mitragynine pseudoindoxyl found that 35 featured appealing flavors, 32 used brightly colored packaging, and 39 were sold as chewable tablets.

"The branding creates a false sense of safety for unknowing consumers who may equate the term 'botanical' with lower risk," the DEA order noted. "Furthermore, there is a paucity of data on quality control or standardized dosage available for these products, making their use especially dangerous."

The use of fruity flavors and chewable forms, federal regulators concluded, appears calculated to appeal to younger consumers — a marketing approach that has drawn particular scrutiny as adolescent overdose deaths involving synthetic opioids have risen.

What the order covers

The temporary scheduling order makes explicit that the action applies to "deliberately manufactured and concentrated opioid products, not traditional botanical kratom." The distinction matters for both law enforcement and consumers: raw kratom leaf remains unscheduled under federal law, while the concentrated synthetic derivatives now carry Schedule I penalties.

Preclinical evidence indicates that all three compounds are potent mu-opioid receptor agonists and may present risks associated with other opioids in this class, including dependence and respiratory depression. Under the Controlled Substances Act, the attorney general may temporarily schedule substances for up to two years while the agency gathers additional data to support permanent classification.

"These are potent opioids being manufactured and sold in consumer products, often under labels that obscure their true risks," Attorney General Todd Blanche said in a Department of Justice press release. "The Justice Department is acting before these dangerous compounds become a broader threat."

Clinical and public health implications

The DEA order highlighted a documented case of a 34-year-old man whose progression illustrated the addiction potential of these compounds. Beginning with powdered kratom, he advanced to 7-hydroxymitragynine tablets and then to mitragynine pseudoindoxyl, ultimately consuming nine 20-mg doses daily. When attempting to reduce his intake, he experienced opioid withdrawal symptoms including hypertension, tachycardia, severe body aches, gastrointestinal distress, and chills, requiring supportive management for three to four days before transitioning to naltrexone depot injections.

The case underscores what addiction specialists have observed in clinical settings: while traditional kratom use carries its own risks, the synthetic derivatives represent a qualitatively different threat profile due to their enhanced potency and concentrated formulation.

The temporary scheduling aligns with broader federal regulatory efforts to address novel psychoactive substances. In July 2025, the Food and Drug Administration raised concerns about 7-hydroxymitragynine and urged the DEA to classify it as a Schedule I drug. The current order represents the agency's most significant enforcement action against kratom-derived compounds to date.

Enforcement and next steps

With the temporary order now in effect, anyone manufacturing, distributing, or possessing the three scheduled compounds faces federal criminal prosecution under Schedule I statutes. The DEA will coordinate with state and local law enforcement to remove products from retail channels.

For individuals struggling with dependence on these or other opioid substances, medication-assisted treatment programs remain available nationwide. Buprenorphine and naltrexone have demonstrated effectiveness in treating opioid use disorder, including dependence on novel synthetic opioids.

The temporary scheduling initiates a period during which the DEA will gather additional data on the compounds' pharmacology, abuse potential, and public health impact. Interested parties may submit comments to the Federal Register docket as the agency considers whether to make the Schedule I classification permanent.